Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia

Published:2017-01-11 Issue:10 Volume:31 Page:2037-2047
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Peirs S^ORCID,Frismantas V,Matthijssens F,Van Loocke W,Pieters T,Vandamme N,Lintermans B,Dobay M P,Berx G,Poppe B,Goossens S,Bornhauser B C,Bourquin J-P,Van Vlierberghe P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201710.pdf

Reference57 articles.

1. Pui C-H, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.

2. Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP et al. A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014; 28: 2336–2343.

3. Pui CH, Mullighan CG, Evans WE, Relling MV . Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120: 1165–1174.

4. Bhojwani D, Pui CH . Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013; 14: e205–e217.

5. Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma;Leukemia & Lymphoma;2024-09

2. Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor);2024-07-29

3. Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers;Frontiers in Immunology;2023-12-18

4. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

5. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer;Bioorganic Chemistry;2023-11